TauRx Therapeutics

Journal of Prevention of Alzheimer’s Disease publishes trial results showing HMTM potentially offers accessible oral treatment option for patients with early Alzheimer’s disease

26 January 2026 -- Scotland, UK -- TauRx Therapeutics Management Ltd today announced results from its Phase III LUCIDITY trial evaluating the efficacy and safety of hydromethylthionine mesylate (HMTM) in the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) have been published in The Journal of Prevention of Alzheimer's Disease. The trial...
395 King Street Aberdeen AB24 5RP United Kingdom